Evidence map›Paper›PMID 29133460›Full record

ArticleMolecular and cellular biology2018

Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.

Weidan Peng, Narumi Furuuchi, Ludmila Aslanukova, Yu-Hung Huang, Samantha Z Brown, Wei Jiang, Sankar Addya, Vikalp Vishwakarma, Erika Peters, Jonathan R Brody and 2 more

Abstract read
In one paragraph

Article in Molecular and cellular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Embryonic Lethal Abnormal Visual-Like Protein 1 Aggravates Caerulein-Induced AR42J Cell Injury and Macrophage M1 Polarization to Accelerate Acute Pancreatitis by Upregulating TRAF6.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. CMTM6 as a master regulator of PD-L1.Cancer immunology, immunotherapy : CII · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Weidan PengLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Narumi FuruuchiLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Ludmila AslanukovaLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Yu-Hung HuangLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Samantha Z BrownSidney Kimmel Cancer Center at the Jefferson Pancreatic, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Wei JiangSidney Kimmel Cancer Center at the Jefferson Pancreatic, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sankar AddyaSidney Kimmel Cancer Center at the Jefferson Pancreatic, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Vikalp VishwakarmaUniversity of Kansas Medical Center, Kansas City, Kansas, USA.
Erika PetersUniversity of Kansas Medical Center, Kansas City, Kansas, USA.
Jonathan R BrodySidney Kimmel Cancer Center at the Jefferson Pancreatic, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Dan A DixonUniversity of Kansas Medical Center, Kansas City, Kansas, USA.
Janet A SawickiLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA sawickij@mlhs.org.
Lankenau Institute for Medical Research · USUniversity of Kansas Medical Center · USSidney Kimmel Cancer Center · USThomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9M
Post-Transcriptional Regulation in Colorectal CancerR01CA134609 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI DIXON, DAN ALAN · 2009 to 2013
$1.4M
NCI NIH HHS P30 CA056036NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA134609NCI NIH HHS R01 CA212600
6 · The paper itself

Abstract

Human antigen R (ELAVL1; HuR) is perhaps the best-characterized RNA-binding protein. Through its overexpression in various tumor types, HuR promotes posttranscriptional regulation of target genes in multiple core signaling pathways associated with tumor progression. The role of HuR overexpression in pancreatic tumorigenesis is unknown and led us to explore the consequences of HuR overexpression using a novel transgenic mouse model that has a >2-fold elevation of pancreatic HuR expression. Histologically, HuR-overexpressing pancreas displays a fibroinflammatory response and other pathological features characteristic of chronic pancreatitis. This pathology is reflected in changes in the pancreatic gene expression profile due, in part, to genes whose expression changes as a consequence of direct binding of their respective mRNAs to HuR. Older mice develop pancreatic steatosis and severe glucose intolerance. Elevated HuR cooperated with mutant K-ras

Indexed as

AnimalsCarcinoma, Pancreatic DuctalCytoplasmELAV-Like Protein 1FemaleGene Expression RegulationGene Expression Regulation, NeoplasticMaleMice, Inbred C57BLMice, TransgenicPancreasPancreatic NeoplasmsPancreatitisPapillomaProto-Oncogene Proteins p21(ras)ELAVL1 protein, humanElavl1 protein, mouseELAV-Like Protein 1Hras protein, mouseProto-Oncogene Proteins p21(ras)cancerHuRinflammationpancreas

Identifiers

PMID29133460
PMCPMC5770537
OpenAlexW2769260650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.